News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
700,528 Results
Type
Article (39755)
Company Profile (247)
Press Release (660526)
Multimedia
Podcasts (51)
Webinars (12)
Section
Business (204196)
Career Advice (2008)
Deals (35423)
Drug Delivery (95)
Drug Development (81055)
Employer Resources (172)
FDA (16191)
Job Trends (14866)
News (345244)
Policy (32548)
Tag
Academia (2555)
Accelerated approval (5)
Adcomms (21)
Allergies (86)
Alliances (49454)
ALS (96)
Alzheimer's disease (1387)
Antibody-drug conjugate (ADC) (133)
Approvals (16188)
Artificial intelligence (265)
Autoimmune disease (22)
Automation (17)
Bankruptcy (360)
Best Places to Work (11637)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (175)
Bladder cancer (81)
Brain cancer (27)
Breast cancer (296)
Cancer (2345)
Cardiovascular disease (181)
Career advice (1677)
Career pathing (30)
CAR-T (161)
Cell therapy (447)
Cervical cancer (20)
Clinical research (66130)
Collaboration (865)
Company closure (2)
Compensation (574)
Complete response letters (19)
COVID-19 (2591)
CRISPR (41)
C-suite (252)
Cystic fibrosis (102)
Data (2381)
Decentralized trials (2)
Denatured (19)
Depression (44)
Diabetes (278)
Diagnostics (6388)
Digital health (20)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (122)
Drug pricing (105)
Drug shortages (25)
Duchenne muscular dystrophy (100)
Earnings (87255)
Editorial (39)
Employer branding (21)
Employer resources (146)
Events (112766)
Executive appointments (749)
FDA (17590)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (781)
Gene editing (109)
Generative AI (20)
Gene therapy (322)
GLP-1 (723)
Government (4432)
Grass and pollen (4)
Guidances (174)
Healthcare (18822)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (126)
Indications (29)
Infectious disease (2736)
Inflammatory bowel disease (143)
Inflation Reduction Act (9)
Influenza (52)
Intellectual property (99)
Interviews (312)
IPO (16533)
IRA (40)
Job creations (3633)
Job search strategy (1422)
Kidney cancer (10)
Labor market (43)
Layoffs (475)
Leadership (17)
Legal (7912)
Liver cancer (76)
Lung cancer (328)
Lymphoma (164)
Machine learning (9)
Management (58)
Manufacturing (331)
MASH (79)
Medical device (13389)
Medtech (13394)
Mergers & acquisitions (19476)
Metabolic disorders (718)
Multiple sclerosis (85)
NASH (16)
Neurodegenerative disease (98)
Neuropsychiatric disorders (28)
Neuroscience (1959)
NextGen: Class of 2025 (6512)
Non-profit (4481)
Now hiring (41)
Obesity (377)
Opinion (205)
Ovarian cancer (82)
Pain (91)
Pancreatic cancer (88)
Parkinson's disease (157)
Partnered (22)
Patents (248)
Patient recruitment (119)
Peanut (46)
People (57366)
Pharmaceutical (63)
Pharmacy benefit managers (20)
Phase I (20610)
Phase II (29133)
Phase III (21678)
Pipeline (1453)
Policy (147)
Postmarket research (2564)
Preclinical (8771)
Press Release (64)
Prostate cancer (108)
Psychedelics (30)
Radiopharmaceuticals (247)
Rare diseases (389)
Real estate (5908)
Recruiting (65)
Regulatory (22335)
Reports (48)
Research institute (2321)
Resumes & cover letters (349)
Rett syndrome (6)
RNA editing (5)
RSV (42)
Schizophrenia (72)
Series A (135)
Series B (91)
Service/supplier (11)
Sickle cell disease (54)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3580)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (52)
The Weekly (30)
Vaccines (700)
Venture capitalists (42)
Weight loss (237)
Women's health (36)
Worklife (16)
Date
Today (254)
Last 7 days (972)
Last 30 days (3512)
Last 365 days (32482)
2025 (12401)
2024 (35218)
2023 (40076)
2022 (51173)
2021 (55711)
2020 (54084)
2019 (46538)
2018 (35019)
2017 (32109)
2016 (31481)
2015 (37554)
2014 (31319)
2013 (26345)
2012 (28572)
2011 (29267)
2010 (27331)
Location
Africa (718)
Alabama (55)
Alaska (7)
Arizona (234)
Arkansas (13)
Asia (37897)
Australia (6198)
California (6553)
Canada (2096)
China (540)
Colorado (280)
Connecticut (284)
Delaware (159)
Europe (81476)
Florida (973)
Georgia (220)
Idaho (57)
Illinois (554)
India (25)
Indiana (324)
Iowa (11)
Japan (176)
Kansas (107)
Kentucky (24)
Louisiana (11)
Maine (63)
Maryland (932)
Massachusetts (4853)
Michigan (227)
Minnesota (408)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (70)
New Hampshire (63)
New Jersey (1819)
New Mexico (28)
New York (1835)
North Carolina (1001)
North Dakota (8)
Northern California (2897)
Ohio (213)
Oklahoma (14)
Oregon (34)
Pennsylvania (1447)
Puerto Rico (13)
Rhode Island (33)
South America (1097)
South Carolina (27)
South Dakota (1)
Southern California (2457)
Tennessee (108)
Texas (971)
United States (24437)
Utah (191)
Virginia (155)
Washington D.C. (64)
Washington State (575)
West Virginia (3)
Wisconsin (58)
700,528 Results for "osel inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Osel Obtains Exclusive License from Danish Research Consortia for IP Related to Osel’s LACTIN-V in Women Undergoing In-Vitro Fertilization
Osel, Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, today announced that it has entered into a definitive agreement with a consortia comprising Aarhus University, Skive Hospital and Statens Serum Institut of Denmark, and obtained the exclusive worldwide license to inventions resulting from an investigator-initiated Phase 2 trial of Osel’s investigational LBP, LACTIN-V,
February 3, 2021
·
2 min read
Biotech Bay
City of Hope and Osel Announce Live Biotherapeutic Product CBM588 May Enhance Efficacy of Immunotherapy for Patients With Metastatic Kidney Cancer
City of Hope and Osel Inc. announced Phase 1 trial data showing that use of the live biotherapeutic CBM588 plus immunotherapy medicine nivolumab/ipilimumab significantly improved progression-free survival in patients with metastatic kidney cancer when compared to use of nivolumab/ipilimumab alone.
February 28, 2022
·
6 min read
Press Releases
CB Scientific, Inc. (CBSC) Announces Corporate Name Change to Cardiac Biotech Solutions, Inc.
May 8, 2025
·
4 min read
Press Releases
Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.
May 7, 2025
·
3 min read
Business
City of Hope and Osel Announce Exclusive License for Intellectual Property on the Use of Live Biotherapeutic Product CBM588 for Oncology Therapeutic Applications
City of Hope and Osel, Inc. today announced that City of Hope has granted an exclusive worldwide license to Osel for intellectual property on the novel use of a LBP CBM588 to enhance efficacy of checkpoint inhibitors to treat cancer, including metastatic renal cell carcinoma.
July 14, 2021
·
4 min read
Press Releases
CorMedix Inc. to Participate in the RBC Global Healthcare Conference
May 15, 2025
·
1 min read
Press Releases
PreveCeutical Medical Inc. Announces Launch of New Website for BioGene Therapeutics Inc., Expanding Its Digital Presence to Enhance Accessibility and Awareness of Innovative Therapies
May 14, 2025
·
2 min read
Press Releases
Exagen Inc. Prices Public Offering of Common Stock
May 8, 2025
·
3 min read
Press Releases
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025
May 7, 2025
·
5 min read
Press Releases
Co-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference
May 15, 2025
·
1 min read
1 of 70,053
Next
